11-October-2016 — Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease. More.
30-August-2016 — CSL today announced that the FDA has accepted for review CSL Behring’s BLA for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent HAE attacks. More.
Other recent news:
17-August-2016— Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 Sep 2016. Mr John Akehurst, has indicated his intention to retire at the conclusion of the Company’s AGM on 12 Oct 2016. More.
4-July-2016— CSL will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland. More.
10-June-2016 — Last night CSL Behring’s Australian facility was awarded ‘2016 Victorian Manufacturer of the Year’ at the Victorian Manufacturing Hall of Fame Awards. More.